Patents by Inventor John T. Potts, Jr.
John T. Potts, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8568736Abstract: Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: March 21, 2008Date of Patent: October 29, 2013Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald T. Juppner
-
Patent number: 8568737Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Publication number: 20130116180Abstract: Disclosed are two PTH analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, that have long-acting activity at the PTH receptor, as demonstrated both in vitro and in vivo. These polypeptides are thus particularly useful in the treatment of diseases, such as hypoparathyroidism, in which long-acting activity is desired. The method of making the analog polypeptides is also disclosed.Type: ApplicationFiled: May 12, 2011Publication date: May 9, 2013Applicants: Chugai Seiyaku Kabushiki Kaisha, The General Hospital CorporationInventors: Thomas J. Gardella, John T. Potts, JR., Harald Juppner, Makoto Okazaki
-
Patent number: 8143374Abstract: The present invention is related to novel parathyroid hormone polypeptide derivatives, and to pharmaceutical composition containing the polypeptides, as well as synthetic and recombinant methods for producing the polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing the polypeptides of the present invention. The present invention further provides diagnostic and therapeutic methods using the polypeptide derivatives.Type: GrantFiled: August 3, 2007Date of Patent: March 27, 2012Assignee: The General Hospital CorporationInventors: Henry M. Kronenberg, John T. Potts, Jr., Thomas J. Gardella
-
Publication number: 20110172153Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: ApplicationFiled: August 1, 2008Publication date: July 14, 2011Applicants: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Patent number: 7910544Abstract: The invention provides novel P1R polypeptide antagonists. These antagonists contain amino acid substitutions at selected positions in truncated PTH and PRHrP polypeptides and function by binding selectively to the juxtamembrane (“J”) domain of the receptor. The J domain is the region of the receptor that spans the seven transmembrane domain and the extracellular loops.Type: GrantFiled: July 16, 2004Date of Patent: March 22, 2011Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Naoto Shimizu, Henry M. Kronenberg, John T. Potts, Jr.
-
Publication number: 20110009328Abstract: Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: ApplicationFiled: March 21, 2008Publication date: January 13, 2011Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Thomas J. GARDELLA, Henry M. Kronenberg, John T. Potts, JR., Harald T. Jüppner
-
Patent number: 7795220Abstract: The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs and derivatives of those analogs. The invention also provides methods of preparing and using the PTH analogs. Further, the invention encompasses compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising camp levels in cells where deemed necessary.Type: GrantFiled: March 19, 2003Date of Patent: September 14, 2010Assignees: The General Hospital Corporation, Bristol-Myers Squibb CompanyInventors: Thomas J. Gardella, John T. Potts, Jr., Henry M. Kronenberg, Naoto Shimizu
-
Publication number: 20100081612Abstract: The present invention is related to novel parathyroid hormone polypeptide derivatives, and to pharmaceutical composition containing the polypeptides, as well as synthetic and recombinant methods for producing the polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing the polypeptides of the present invention. The present invention further provides diagnostic and therapeutic methods using the polypeptide derivatives.Type: ApplicationFiled: August 3, 2007Publication date: April 1, 2010Applicant: The General Hospital CorporationInventors: Henry M. Kronenberg, John T. Potts, JR., Thomas J. Gardella
-
Publication number: 20090264365Abstract: The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs, and methods of preparing and using the PTH analogs. The invention provides novel PTH polypeptide derivatives containing amino acid substitutions at selected positions in the polypeptides. The invention provides derivatives of PTH(1-34), PTH(1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11), and PTH(1-10) polypeptides, wherein at least one residue in each polypeptide is a helix, preferably an ?-helix, stabilizing residue. The invention also provides methods of making such peptides. Further, the invention encompasses compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g., in treating fractures or cartilage disorders and for raising cAMP levels in cells where deemed necessary.Type: ApplicationFiled: June 9, 2009Publication date: October 22, 2009Applicant: The General Hospital CorporationInventors: Thomas J. GARDELLA, Naoto Shimizu, Henry M. Kronenberg, John T. Potts, JR.
-
Patent number: 7479478Abstract: The present invention is related to synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28). Some of the peptides of the invention are at least 90% identical to a peptide consisting essentially of the amino acid sequence X01ValSerGluIleGlnLeuMetHis AsnLeuGlyLysHisLeuAsnSer MetX02ArgValGluTrpLeuArgLysLysLeu (SEQ ID NO:1), wherein X01 is Ser, Ala or Gly; and X02 is Glu or Arg.Type: GrantFiled: October 7, 2004Date of Patent: January 20, 2009Assignee: The General Hospital CorporationInventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella, John T. Potts, Jr.
-
Publication number: 20080300165Abstract: This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.Type: ApplicationFiled: November 4, 2005Publication date: December 4, 2008Applicant: The General Hospital CorporationInventors: Mark C. Poznansky, John T. Potts, JR., Fabrizio Vianello, Natalia Papeta
-
Patent number: 7371844Abstract: Parathyroid hormone(PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: July 8, 2005Date of Patent: May 13, 2008Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Juppner
-
Patent number: 7244834Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1–34) fragment are disclosed that combine the N-terminal signaling domain (residues 1–9) and the C-terminal binding domain (residues 15–31) via a linker. Nucleic acid molecules and peptides for PTH(1–9)-(Gly)5-PTH(15–31) (PG5) and PTH(1–9)-(Gly)7-PTH(15–31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: GrantFiled: March 3, 2006Date of Patent: July 17, 2007Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Patent number: 7153951Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.Type: GrantFiled: July 11, 2002Date of Patent: December 26, 2006Assignee: The General Hospital CorporationInventors: Thomas J Gardella, Henry M Kronenberg, John T Potts, Jr., Harald Jüppner
-
Patent number: 7150974Abstract: DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.Type: GrantFiled: November 24, 1998Date of Patent: December 19, 2006Assignee: The General Hospital CorporationInventors: Gino V. Segre, Henry M. Kronenberg, Abdul-Badi Abou-Samra, Harald Juppner, John T. Potts, Jr., Ernestina Schipani
-
Patent number: 7132260Abstract: DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.Type: GrantFiled: October 9, 2002Date of Patent: November 7, 2006Assignee: The General Hospital CorporationInventors: Gino V. Segre, Henry M. Kronenberg, Abdul-Badi Abou-Samra, Harald Juppner, John T. Potts, Jr., Ernestina Schipani
-
Patent number: 7057012Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1–34) fragment are disclosed that combine the N-terminal signaling domain (residues 1–9) and the C-terminal binding domain (residues 15–31) via a linker. Nucleic acid molecules and peptides for PTH(1–9)-(Gly)5-PTH(15–31) (PG5) and (1–9)-(Gly)7-PTH(15–31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: GrantFiled: December 30, 1999Date of Patent: June 6, 2006Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Patent number: 7022815Abstract: Novel parathyroid hormone(PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: September 29, 2000Date of Patent: April 4, 2006Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Patent number: 6803213Abstract: The present invention is related to a synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28). Some of the peptides of the invention are at least 90% identical to a peptide consisting essentially of the amino acid sequence X01ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMetX02ArgValGluTrpLeuArgLysLysLeu (SEQ ID NO:1), wherein X01 is Ser, Ala or Gly; and X02 is Glu or Arg.Type: GrantFiled: May 30, 2002Date of Patent: October 12, 2004Assignee: The General Hospital CorporationInventors: F. Richard Bringhurst, Hisashi Takasu, Thomas J. Gardella, John T. Potts, Jr.